A HOT TOPIC IN DRUG DEVELOPMENT AND RESEARCH

Reliable, objective and easy-to-interpret results in just three hours

Svar Life Sciences' solution for assessment and characterization of complement function is an ELISA based assay system developed in collaboration with an extensive KOL network[1]. The test system enables pathway-specific determination of activation while eliminating interference from other pathways and delivers fast, reliable and objective assessment of complement function.



A VALUABLE TOOL IN COMPLEMENT-DIRECTED DRUG DISCOVERY

Development of complement targeting drugs

The incitement for developing complement manipulating drugs has grown dramatically over the last decade in response to the increased awareness of the importance of complement activity in a variety of clinical conditions. This new perception of the role of complement in health and disease highlights the promise of intervention in the complement cascade[2].

Our complement activation assays support and accelerate different steps of development. Besides functional activation of human samples they can be used with a variety of species like swein or non-human primates[3,4,5,9].

A unique bioanalytical solution

Our functional complement assays are used in drug discovery, drug development and offer the possibility to screen for drug effects throughout the entire cascade. They are recognized for their ability to assess efficacy and potency of complement targeting **methods** aiming on inhibiting or enhancing the complement functionality[4,5,6].

Monitoring of complement function/activity is valuable in the development and optimization of treatment regimens for complement related diseases. Examples are studies evaluating new treatment concepts for diseases involving dysfunctionality of the complement system, and algorithms for drugs modulating the complement system directly[7,8,9,10].

Under certain circumstances complement activation can be devastating and cause severe reactions. Off-target complement activation can be caused by artificial surfaces, nanoparticles, drug candidates (e.g. CARPA - Complement activation-related pseudo allergy or non-IgE mediated hypersensitivity reaction). Svar Life Science offers various solutions for monitoring such complement-related side effects[11,12].

Distributed by:

IBL AMERICA

Immuno-Biological Laboratories, Inc.
8201 Central Ave NE, Suite P
Minneapolis, MN 55432

Toll-Free: 888-523-1246
Email: info@IBL-America.com
Web: www.IBL-America.com



APPRECIATED BY CUSTOMERS IN BIOTECH AND PHARMA

The well-established ELISA technology offers a robust and standardized assay platform, delivering fast and reliable results within three hours. Results are easy to interpret, and the format of the assay can be used with a wide variety of open systems, individual research protocols and automation.

FEATURES	BENEFITS
• **Well established ELISA technology** - Robust, standardized assays detecting complement deficiencies of all three pathways selectively. Results within three hours • Allows for a complete **assessment of all three pathways simultaneously**. No interference between pathways • Similar assay procedure for all three pathways. **Proven correlation** with haemolytic assays (CH50, AH50)	**Fast, reliable & proven**
• **Multifunctional ELISA kit** - assay adaptations possible for individual research protocols, validated protocols available for automation: high-throughput option	**Flexible format**
• Allows for testing effect/potency of **any inhibitory drug at any level and any pathway** • Complement function testing also **verifies the effect of certain treatments** • **Works in human, non-human primates** and swein	**Valuable tool in research and development applications**

THE COMPLEMENT SYSTEM - AT A GLANCE

The complement system is an essential part of the innate immune system and involves more than 50 soluble and cell-bound proteins. Complement activation occurs via three different pathways - classical, alternative and lectin - and each step of the proteolytic cascade is highly regulated.

The system interacts with the adaptive immune system and cross-talks with the coagulation system. It plays an important role during infections and is heavily involved in the development of several inflammatory and degenerative diseases. Consequently, the complement system is a matter of extensive research and fundamental for innovative and promising new treatment regimens[13].

References

1. Seelen MA et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. *J Immunol Meth 2005; 296: 187–198*
2. Zelek WM, Xie L, Morgan BP, Harris CL. Compendium of current complement therapeutics. *Mol Immunol. 2019 Oct;114:341-352*
3. Persson N et al. Exploring existing human complement C4d, TCC and functional activity assays, for assessment of complement activation in laboratory animals. *Abstract 86 European Meeting on Complement in Human Disease (EMCHD) 2019*
4. Kusne et al. Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis. *Mol Ther Methods Clin Dev. 2019 May 10;13:484-492*
5. Yuan et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. *Haematologica. 2017 Mar;102(3):466-475*
6. Bartko et al. A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway. *Clin Pharmacol Ther. 2018 Oct;104(4):655-663*
7. Volokhina E B et al.. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. *Clin Immunol 2015; 160: 237–43*
8. Bjerre A, Mollnes TE et al. Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome. *Case Rep Nephrol. 2018 Dec 18;2018:3810249*
9. Castellano G et al. Therapeutic Targeting of Classical and Lectin Pathways of Complement Protects from Ischemia-Reperfusion-Induced Renal Damage. *Am J Pathol 2010; 176:1648–1659*
10. Selvaskandan et al. Inhibition of the Lectin Pathway of the Complement System as a Novel Approach in the Management of IgA Vasculitis-Associated Nephritis. *Nephron. 2020;144(9):453-458.*
11. Brennan FR. In vitro assays supporting the safety assessment of immunomodulatory monoclonal antibodies. *Toxicol In Vitro. 2017 Dec;45(Pt 3):296-308*
12. Fülöp T et al. Infusion Reactions Associated with the Medical Application of Monoclonal Antibodies: The Role of Complement Activation and Possibility of Inhibition by Factor H. *Antibodies (Basel) 2018 Mar 14;7(1)*
13. Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. *Nat Rev Drug Discov. 2019 Sep;18(9):707-729*

Doc No: E-210-GB05, September 2020

Distributed by:

Immuno-Biological Laboratories, Inc.
8201 Central Ave NE, Suite P
Minneapolis, MN 55432

Toll-Free: 888-523-1246
Email: info@IBL-America.com
Web: www.IBL-America.com